Company profile
Ernexa Therapeutics Inc.
NASDAQ: ERNA · Healthcare · Biotechnology
#923 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
43DFH 25DQ 69GM 42SS 49
v0.1 · 65/100 weight · provisional
↑ listing tenure, revenue growth (YoY) · ↓ return on equity, 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$14.1M
Employees
5
as of 2026-08-25
Market cap
$1.6M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$582.0k$582.0k2024
Net income-$14.1M-$14.1M2025
Operating income-$9.3M-$9.3M2025
Total assets$5.8M$5.8M2025
Liabilities$3.4M$3.4M2025
Equity$2.4M$2.4M2025
Revenue trend
FY2016 – FY2024 · USD
FY16
FY18
FY18
FY19
FY20
FY23
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Ernexa Therapeutics Inc.’s revenue?
Ernexa Therapeutics Inc. booked $582.0k in FY2024 revenue, growing 756% year over year — faster than 95% of Healthcare companies we track, at a -2419.9% net margin.
Peers · Healthcare
PMGC Holdings Inc.29DGrapefruit USA, Inc.——Theralase Technologies Inc.37DViropro Inc.——VYNE Therapeutics Inc.38DTrevena, Inc.——Neighbors
Middlesex →Key facts
CEOSanjeev Luther
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: ERNA
Employees5
IPO date1991-08-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.